Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Is Fenofibrate a Reasonable Treatment for Diabetic Microvascular Disease?
Authors
Keywords
Diabetes, Diabetic retinopathy, Diabetic nephropathy, Diabetic neuropathy, Fenofibrate, Clinical studies, Experimental studies
Journal
Current Diabetes Reports
Volume 15, Issue 5, Pages -
Publisher
Springer Nature
Online
2015-03-16
DOI
10.1007/s11892-015-0599-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of fenofibrate on retinal neurodegeneration in an experimental model of type 2 diabetes
- (2014) Patricia Bogdanov et al. ACTA DIABETOLOGICA
- Peroxisome Proliferator–Activated Receptor α Protects Capillary Pericytes in the Retina
- (2014) Lexi Ding et al. AMERICAN JOURNAL OF PATHOLOGY
- Costs of Diabetes Mellitus (CoDiM) in Germany, Direct Per-capita Costs of Managing Hyperglycaemia and Diabetes Complications in 2010 Compared to 2001
- (2014) I. Köster et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Effects of the PPAR-α Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia
- (2014) Thavarak Ouk et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Effects of Fenofibric Acid on Diabetic Macular Edema: The MacuFen study
- (2014) Pascale Massin et al. OPHTHALMIC EPIDEMIOLOGY
- Therapeutic Effects of Fenofibrate on Diabetic Peripheral Neuropathy by Improving Endothelial and Neural Survival in db/db Mice
- (2014) Ye Rim Cho et al. PLoS One
- The db/db Mouse: A Useful Model for the Study of Diabetic Retinal Neurodegeneration
- (2014) Patricia Bogdanov et al. PLoS One
- Fenofibrate Improves Renal Lipotoxicity through Activation of AMPK-PGC-1α in db/db Mice
- (2014) Yu Ah Hong et al. PLoS One
- Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus
- (2013) Frank M. Sacks et al. CIRCULATION
- Fenofibrate: A New Treatment for Diabetic Retinopathy. Molecular Mechanisms and Future Perspectives
- (2013) Rafael Simo et al. CURRENT MEDICINAL CHEMISTRY
- Global estimates of diabetes prevalence for 2013 and projections for 2035
- (2013) L. Guariguata et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Pathogenic role of diabetes-induced PPAR- down-regulation in microvascular dysfunction
- (2013) Y. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives
- (2013) Rafael Simó et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Molecular Implications of the PPARs in the Diabetic Eye
- (2013) Andreea Ciudin et al. PPAR Research
- Meta-Analysis of Safety of the Coadministration of Statin With Fenofibrate in Patients With Combined Hyperlipidemia
- (2012) Jinrui Guo et al. AMERICAN JOURNAL OF CARDIOLOGY
- Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications
- (2012) Rafael Simó et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
- (2012) Ying Chen et al. DIABETES
- Reversibility of Fenofibrate Therapy-Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
- (2012) J. C. Mychaleckyj et al. DIABETES CARE
- Global Prevalence and Major Risk Factors of Diabetic Retinopathy
- (2012) J. W. Y. Yau et al. DIABETES CARE
- Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
- (2012) N. Hex et al. DIABETIC MEDICINE
- Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
- (2012) D. E. Bonds et al. DIABETOLOGIA
- Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy
- (2012) Supriya Kadian et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation
- (2011) M. Villarroel et al. DIABETOLOGIA
- Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions
- (2011) Soledad Miranda et al. JOURNAL OF CELLULAR PHYSIOLOGY
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
- (2011) Goodarz Danaei et al. LANCET
- Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus
- (2011) George L. Bakris MAYO CLINIC PROCEEDINGS
- The impact of diabetes mellitus on healthcare costs in Italy
- (2011) Carlo B Giorda et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States
- (2010) Carol E. Koro et al. CLINICAL THERAPEUTICS
- Prevalence and healthcare costs of diabetic retinopathy: a population-based register study in Sweden
- (2010) E. Heintz et al. DIABETOLOGIA
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy
- (2010) Lingyun Li et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Diabetic retinopathy
- (2010) Ning Cheung et al. LANCET
- Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy
- (2009) C. Forsblom et al. DIABETES CARE
- Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
- (2009) Kushwin Rajamani et al. LANCET
- Economic Outcomes Associated with Microvascular Complications of Type 2 Diabetes Mellitus
- (2009) Elise M. Pelletier et al. PHARMACOECONOMICS
- Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People
- (2008) Jean-Claude Ansquer et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Direct and indirect costs among employees with diabetic retinopathy in the United States
- (2008) Lauren J. Lee et al. CURRENT MEDICAL RESEARCH AND OPINION
- Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study
- (2008) T. M. E. Davis et al. DIABETOLOGIA
- Effects of Intensive Glucose Lowering in Type 2 Diabetes
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Diabetic neuropathy: Mechanisms to management
- (2008) James L. Edwards et al. PHARMACOLOGY & THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation